JP2022528005A5 - - Google Patents
Info
- Publication number
- JP2022528005A5 JP2022528005A5 JP2021560478A JP2021560478A JP2022528005A5 JP 2022528005 A5 JP2022528005 A5 JP 2022528005A5 JP 2021560478 A JP2021560478 A JP 2021560478A JP 2021560478 A JP2021560478 A JP 2021560478A JP 2022528005 A5 JP2022528005 A5 JP 2022528005A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence number
- seq
- nucleic acid
- containing sequence
- vlcdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024206358A JP2025041629A (ja) | 2019-04-01 | 2024-11-27 | 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962827744P | 2019-04-01 | 2019-04-01 | |
| US62/827,744 | 2019-04-01 | ||
| PCT/US2020/025936 WO2020205849A1 (en) | 2019-04-01 | 2020-03-31 | Btla-binding (cd272) antibodies for modulating immune response and treating disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024206358A Division JP2025041629A (ja) | 2019-04-01 | 2024-11-27 | 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022528005A JP2022528005A (ja) | 2022-06-07 |
| JP2022528005A5 true JP2022528005A5 (https=) | 2023-04-07 |
| JP7596298B2 JP7596298B2 (ja) | 2024-12-09 |
Family
ID=70296156
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021560478A Active JP7596298B2 (ja) | 2019-04-01 | 2020-03-31 | 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体 |
| JP2024206358A Pending JP2025041629A (ja) | 2019-04-01 | 2024-11-27 | 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024206358A Pending JP2025041629A (ja) | 2019-04-01 | 2024-11-27 | 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11384146B2 (https=) |
| EP (1) | EP3946622A1 (https=) |
| JP (2) | JP7596298B2 (https=) |
| KR (1) | KR20220047536A (https=) |
| CN (2) | CN114585416B (https=) |
| CA (1) | CA3135836A1 (https=) |
| IL (1) | IL286838A (https=) |
| WO (1) | WO2020205849A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023546713A (ja) * | 2020-10-23 | 2023-11-07 | アナプティスバイオ インコーポレイティッド | Ｂ及びｔリンパ球アテニュエータ（ｂｔｌａ）調節因子及びその使用方法 |
| MX2024007054A (es) * | 2021-12-10 | 2024-09-04 | Merck Sharp & Dohme Llc | Aglutinantes de mesotelina humana. |
| US20250304693A1 (en) * | 2022-01-29 | 2025-10-02 | Hifibio, Inc. | Anti-btla antibodies and uses thereof in treating cancer |
| US20230322929A1 (en) * | 2022-04-12 | 2023-10-12 | Shanghai Junshi Biosciences Co., Ltd. | Compositions and Methods for Treating Solid Tumors with Anti-BTLA as Mono or Combination Therapy |
| CN120322455A (zh) * | 2022-07-19 | 2025-07-15 | 舒泰神(加州)生物科技有限公司 | 特异性识别b和t淋巴细胞衰减器(btla)的抗体及其应用 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2025250861A1 (en) * | 2024-05-31 | 2025-12-04 | Icahn School Of Medicine At Mount Sinai | Broadly neutralizing anti-hcmv antibodies and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| EP1560593B1 (en) | 2002-10-25 | 2016-04-20 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
| AU2004297616B2 (en) | 2003-12-04 | 2008-12-18 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| MY151191A (en) * | 2007-09-26 | 2014-04-30 | Genentech Inc | Novel antibodies |
| BR112012007875A2 (pt) * | 2009-07-31 | 2016-11-22 | Medarex Inc | anticorpos totalmente humanos para btla |
| CA2961439A1 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
| EP3288587A4 (en) * | 2015-04-29 | 2018-09-12 | Sanford-Burnham Medical Research Institute | Modulation of immune response using btla agonist antibodies |
| EP3383908A1 (en) * | 2015-12-02 | 2018-10-10 | Stsciences, Inc. | Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator) |
| MX2018010295A (es) * | 2016-02-26 | 2019-06-06 | Inst Nat Sante Rech Med | Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos. |
| KR20230119259A (ko) * | 2016-04-15 | 2023-08-16 | 이뮤넥스트, 인크. | 항-인간 vista 항체 및 이의 용도 |
-
2020
- 2020-03-31 KR KR1020217035131A patent/KR20220047536A/ko active Pending
- 2020-03-31 CA CA3135836A patent/CA3135836A1/en active Pending
- 2020-03-31 CN CN202080040939.4A patent/CN114585416B/zh active Active
- 2020-03-31 US US16/836,006 patent/US11384146B2/en active Active
- 2020-03-31 CN CN202411950244.6A patent/CN119735682A/zh active Pending
- 2020-03-31 WO PCT/US2020/025936 patent/WO2020205849A1/en not_active Ceased
- 2020-03-31 EP EP20720302.7A patent/EP3946622A1/en active Pending
- 2020-03-31 JP JP2021560478A patent/JP7596298B2/ja active Active
-
2021
- 2021-09-30 IL IL286838A patent/IL286838A/en unknown
-
2022
- 2022-07-10 US US17/811,586 patent/US20230340123A1/en active Pending
-
2024
- 2024-11-27 JP JP2024206358A patent/JP2025041629A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022528005A5 (https=) | ||
| JP7386277B2 (ja) | 二重特異性シグナル伝達物質およびその使用 | |
| US20240025980A1 (en) | Therapeutic targeting of non-cellular structures | |
| US12497436B2 (en) | Chimeric protein, and encoding nucleic acid thereof, comprising interferon-β and a targeting moiety comprising a single-domain antibody or single-chain antibody | |
| US20260115254A1 (en) | Immune-cell targeted bispecific chimeric proteins and uses thereof | |
| US20240368277A1 (en) | SIRP1a TARGETED CHIMERIC PROTEINS AND USES THEREOF | |
| US20200069797A1 (en) | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists | |
| US20210261668A1 (en) | Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1 | |
| US20210024631A1 (en) | Bi-functional proteins and construction thereof | |
| AU2024202552A1 (en) | Neutralization of inhibitory pathways in lymphocytes | |
| US12410225B2 (en) | Modulation of dendritic cell lineages | |
| IL269387A (en) | Pan-elr cxc chemokine antibodies | |
| US20240199714A1 (en) | Il-2 based constructs | |
| US20230002493A1 (en) | Pd-l1 targeted chimeric proteins and uses thereof | |
| JP2022522815A5 (https=) | ||
| AU2016330471A1 (en) | Antibodies that bind human cannabinoid 1 (CB1) receptor | |
| JP2022517809A5 (https=) | ||
| TW202539734A (zh) | 使用白細胞介素-17（il-17）拮抗劑治療自體免疫性疾病之方法 | |
| WO2017221174A1 (en) | Methods of treating vitiligo using interleukin-17 (il-17) antibodies | |
| JP2022534494A5 (https=) | ||
| US20240400633A1 (en) | Split human ifn-gamma and tnf-alpha constructs and uses thereof | |
| CN116059377A (zh) | 抗ox40抗体在联合用药中的应用 | |
| US20220378925A1 (en) | Conjugated chimeric proteins | |
| WO2024240247A1 (en) | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 antibodies | |
| JP2022520817A5 (https=) |